LimmaTech Biologics AG is a Swiss biotechnology company focused on the development of vaccines against bacterial pathogens. Its technology platform targets bacterial toxins and superantigens to elicit broad and durable immune responses. The lead candidate, LTB-SA7, is in Phase 1 clinical development for the prevention of Staphylococcus aureus infections, a common cause of surgical-site infections. Additional preclinical programs address Neisseria gonorrhoeae and Chlamydia trachomatis, pathogens associated with long-term reproductive health consequences.
Adds a better-tolerated shingles vaccine, bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae and C. trachomatis, and nanoparticle EBV vaccine tech; deals include milestone payments.
